Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mads Lamm Larsen

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Seminars in Thrombosis and Hemostasis|December 22, 2019
Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery DiseaseMads Lamm Larsen, Erik Lerkevang Grove, Steen Dalby Kristensen, et al.
Lupus|April 2, 2026
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022-2025)Laura Nørgaard, Mads Lamm Larsen, Bent Deleuran, et al.
The American Journal of Case Reports|September 2, 2017
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet TurnoverOliver Heidmann Pedersen, Mads Lamm Larsen, Steen Dalby Kristensen, et al.
Ugeskrift for Laeger|November 22, 2024
Mads Lamm Larsen, Anne Voss, Christoffer Tandrup Holst Nielsen, et al.
The American Journal of Case Reports|September 9, 2024
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical ImplicationsMads Lamm Larsen, Morten Kelder Skouboe, Trine Hyrup Mogensen, et al.
Clinical and Experimental Immunology|July 5, 2023
Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosusMads Lamm Larsen, Anne Troldborg, Erik J M Toonen, et al.
Platelets|February 15, 2018
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosisMads Lamm Larsen, Oliver Heidmann Pedersen, Anne-Mette Hvas, et al.
Cytometry. Part B, Clinical Cytometry|May 24, 2018
Platelet characteristics in patients with essential thrombocytosisOliver Heidmann Pedersen, Mads Lamm Larsen, Erik Lerkevang Grove, et al.
Rheumatology (Oxford, England)|November 29, 2022
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|June 26, 2024
COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of RituximabChristian Ammitzbøll, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Seminars in Thrombosis and Hemostasis|December 22, 2019
Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery DiseaseMads Lamm Larsen, Erik Lerkevang Grove, Steen Dalby Kristensen, et al.
Lupus|April 2, 2026
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022-2025)Laura Nørgaard, Mads Lamm Larsen, Bent Deleuran, et al.
The American Journal of Case Reports|September 2, 2017
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet TurnoverOliver Heidmann Pedersen, Mads Lamm Larsen, Steen Dalby Kristensen, et al.
Ugeskrift for Laeger|November 22, 2024
Mads Lamm Larsen, Anne Voss, Christoffer Tandrup Holst Nielsen, et al.
The American Journal of Case Reports|September 9, 2024
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical ImplicationsMads Lamm Larsen, Morten Kelder Skouboe, Trine Hyrup Mogensen, et al.
Clinical and Experimental Immunology|July 5, 2023
Differentiating between activation via the lectin or the classical complement pathway in patients with systemic lupus erythematosusMads Lamm Larsen, Anne Troldborg, Erik J M Toonen, et al.
Platelets|February 15, 2018
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosisMads Lamm Larsen, Oliver Heidmann Pedersen, Anne-Mette Hvas, et al.
Cytometry. Part B, Clinical Cytometry|May 24, 2018
Platelet characteristics in patients with essential thrombocytosisOliver Heidmann Pedersen, Mads Lamm Larsen, Erik Lerkevang Grove, et al.
Rheumatology (Oxford, England)|November 29, 2022
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Ammitzbøll, Marianne Kragh Thomsen, Jakob Bøgh Andersen, et al.
ACR Open Rheumatology|June 26, 2024
COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of RituximabChristian Ammitzbøll, Marianne Kragh Thomsen, Lars Erik Bartels, et al.
Pageof 2